No Data
No Data
Express News | Allarity Therapeutics Regains Nasdaq Compliance
Express News | Allarity Therapeutics Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement
Express News | Allarity Therapeutics-Amended Sales Agreement to Increase Total Amount of Common Stock That Co May Offer & Sell Under Sales Agreement to $24 Mln
Allarity Therapeutics | 10-Q: Quarterly report
Allarity Therapeutics: Strategic Focus Now Solely on Stenoparib >ALLR
Allarity Therapeutics: Strategic Focus Now Solely on Stenoparib >ALLR
Allarity Therapeutics Requested SEC to Withdraw Form S-1 Filed Last Oct >ALLR
Allarity Therapeutics Requested SEC to Withdraw Form S-1 Filed Last Oct >ALLR
No Data